
Carlsmed Inc (CARL) Stock Forecast & Price Target
Carlsmed Inc (CARL) Analyst Ratings
Bulls say
Carlsmed is positioned for strong growth and potential profitability with positive clinical data and increasing adoption of their Aprevo implants. With a strong patent portfolio and expansion into the degenerative market, the company's hybrid commercial model has resulted in increased utilization and a goal of capturing a significant portion of the US spine surgeon market. While potential risks such as sales execution and market competition exist, the company is expected to reach cash flow breakeven with less than $200 million in revenue and currently holds a Buy rating.
Bears say
Carlsmed is a commercial-stage medical technology company that focuses on AI-driven personalized solutions for spine surgery. While the company's unique approach and differentiated products have led to strong revenue growth, there are concerns about the potential for slower uptake and market volatility. Additionally, competition and potential delays in product launches could negatively impact future revenue and profitability. The company's current valuation appears to be based on optimistic assumptions, and any significant miss in revenue could result in multiple contraction and a decline in stock price.
This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.
Carlsmed Inc (CARL) Analyst Forecast & Price Prediction
Start investing in Carlsmed Inc (CARL)
Order type
Buy in
Order amount
Est. shares
0 shares